Whole-Body Electrical Stimulation in Patients Undergoing Lung Transplantation
Launched by FEDERAL UNIVERSITY OF HEALTH SCIENCE OF PORTO ALEGRE · Feb 6, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called whole-body electrical stimulation (WB-EMS) on patients who are undergoing lung transplantation. The goal is to see if adding WB-EMS to regular physiotherapy can help patients recover better after their surgery. Patients will be placed into two groups: one group will receive the usual physiotherapy, while the other group will get both physiotherapy and WB-EMS every day until they leave the hospital. Researchers will assess patients at several points: before the lung transplant, after they have been taken off the ventilator, during the treatment, and when they are ready to go home.
To be eligible for this trial, patients must be adults aged 18 and older who are set to have a lung transplant and are stable enough to start rehabilitation within a week after their surgery. However, certain conditions, like severe heart problems or infections, may prevent someone from participating. If someone joins the trial, they can expect regular check-ins and treatments designed to support their recovery journey. It's important to know that this study is not yet recruiting participants, so it will start in the near future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing unilateral or bilateral lung transplantation;
- • Admitted to the intensive care unit and without invasive ventilatory support;
- • Hemodynamically stable;
- • Time less than or equal to 7 days between lung transplantation and the beginning of rehabilitation protocols.
- Exclusion Criteria:
- • Patients with severe psychomotor agitation;
- • Recent acute myocardial infarction (24 hours) and / or uncontrolled arrhythmias;
- • Temporary transcutaneous pacemaker;
- • Stroke after lung transplantation;
- • Decompensated heart failure;
- • Uncontrolled hypertension (systolic blood pressure \> 230 mmHg and diastolic blood pressure \> 120 mmHg) or mean arterial pressure \<60 mmHg;
- • Patients who present important hemodynamic changes during training;
- • Peripheral vascular changes in the lower limbs such as untreated deep vein thrombosis;
- • In a feverish state;
- • Patients with epidermal lesions on the thighs that make it impossible to place self-adhesive electrodes for electrical stimulation;
- • Patients with acute renal failure.
About Federal University Of Health Science Of Porto Alegre
The Federal University of Health Science of Porto Alegre (UFCSPA) is a distinguished academic institution in Brazil, dedicated to advancing healthcare education, research, and clinical practice. Renowned for its commitment to excellence in medical and health sciences, UFCSPA plays a pivotal role in fostering innovation through rigorous clinical trials and collaborative research initiatives. The university's research programs are designed to address pressing health challenges, enhance patient care, and contribute to the scientific community, ensuring that findings translate into meaningful health solutions. With a multidisciplinary approach and a focus on ethical standards, UFCSPA is at the forefront of improving health outcomes both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rio Grande Do Sul (Rs), Brazil
Porto Alegre, , Brazil
Patients applied
Trial Officials
Jociane Schardong, PhD
Principal Investigator
Federal University of Health Sciences of Porto Alegre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported